Research programme: erythropoietin depot - Borean PharmaAlternative Names: Erythropoietin - Borean
Latest Information Update: 09 Aug 2007
At a glance
- Originator Borean Pharma
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 09 Aug 2007 Discontinued - Preclinical for Anaemia in Denmark (Parenteral)
- 25 Feb 2004 Preclinical trials in Anaemia in Denmark (Parenteral)